Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Ron N ApteElena Voronov

Abstract

Interleukin-1 (IL-1) comprises a family of closely related genes; the two major agonistic proteins, IL-1alpha and IL-1beta, are pleiotropic and affect mainly inflammation, immunity and haemopoiesis. IL-1beta is active solely in its secreted form, whereas IL-1alpha is active mainly as an intracellular precursor. IL-1 is abundant at tumour sites, where it may affect the process of carcinogenesis, tumour growth and invasiveness and the patterns of tumour-host interactions. Here, we review the effects of micro-environment- and tumour cell-derived IL-1 on malignant processes in experimental tumour models. We propose that membrane-associated IL-1alpha expressed on malignant cells stimulates anti-tumour immunity, while secretable IL-1beta derived from the micro-environment or the malignant cells, activates inflammation that promotes invasiveness and induces tumour-mediated suppression. Inhibition of the function of IL-1 by the inhibitor of IL-1, interleukin-1 receptor antagonist (IL-1Ra), reduces tumour invasiveness and alleviates tumour-mediated suppression, pointing to its feasible use in cancer therapy. Differential manipulation of IL-1alpha and IL-1beta in malignant cells or in the tumour's micro-environment may open new possibili...Continue Reading

References

Feb 1, 1992·International Journal of Cancer. Journal International Du Cancer·M ZöllerR N Apte
Jul 9, 1992·International Journal of Cancer. Journal International Du Cancer·A DouvdevaniR N Apte
Feb 1, 1992·International Journal of Cancer. Journal International Du Cancer·M ZöllerR N Apte
Jun 18, 1998·Annals of the New York Academy of Sciences·A MantovaniM Introna
Nov 24, 1999·The Journal of Experimental Medicine·C Cordon-Cardo, C Prives
Jan 19, 2000·The Journal of Experimental Medicine·M J NicklinG W Duff
Mar 7, 2001·Lancet·F Balkwill, A Mantovani
Mar 21, 2001·The Journal of Experimental Medicine·L M Coussens, Z Werb
Jan 16, 2002·Current Opinion in Immunology·John E Sims
Mar 20, 2002·Cytokine & Growth Factor Reviews·Hiroaki IkedaRobert D Schreiber
Mar 20, 2002·Cytokine & Growth Factor Reviews·Fran Balkwill
Jun 5, 2002·The Journal of Experimental Medicine·Zhihai QinThomas Blankenstein
Jul 12, 2002·Cancer Immunology, Immunotherapy : CII·Sergei Kusmartsev, Dmitry I Gabrilovich
Jul 31, 2002·Seminars in Cancer Biology·Ron N Apte, Elena Voronov
Sep 11, 2002·Cytokine & Growth Factor Reviews·William P Arend
Sep 11, 2002·Cytokine & Growth Factor Reviews·Yoichiro Iwakura
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Dec 20, 2002·Nature·Carl Nathan
Dec 20, 2002·Nature·Lisa M Coussens, Zena Werb
Jan 1, 2003·Seminars in Cancer Biology·Sharon Amit, Yinon Ben-Neriah
Feb 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Elena VoronovRon N Apte
Mar 14, 2003·Current Opinion in Immunology·Thomas Blankenstein, Zhihai Qin
Mar 26, 2003·Seminars in Cancer Biology·Anning Lin, Michael Karin
Sep 11, 2003·The Lancet Oncology·Peter W Szlosarek, Frances R Balkwill
Nov 1, 2003·Cancer Immunology, Immunotherapy : CII·Paolo SerafiniVincenzo Bronte
Jan 7, 2004·Nature Reviews. Cancer·Jeffrey W Pollard
Mar 23, 2004·Annual Review of Immunology·Gavin P DunnRobert D Schreiber
Apr 3, 2004·Nature Reviews. Drug Discovery·Martin Braddock, Anthony Quinn
Aug 3, 2004·Nature Reviews. Immunology·Jukka Vakkila, Michael T Lotze
Aug 17, 2004·Immunity·Gavin P DunnRobert D Schreiber
Aug 27, 2004·Nature·Eli PikarskyYinon Ben-Neriah
Sep 17, 2004·Cell·Hans Clevers
Oct 19, 2004·Seminars in Cancer Biology·Mary PhilipHans Schreiber
Dec 2, 2004·Nature Reviews. Immunology·Dmitry Gabrilovich
Mar 16, 2005·Cancer Cell·Frances BalkwillAlberto Mantovani

❮ Previous
Next ❯

Citations

Nov 1, 2011·Purinergic Signalling·Elizandra BraganholAna Maria O Battastini
Sep 17, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Eileen L HeinrichSteven M Dubinett
Jul 21, 2011·Nature Immunology·Yinon Ben-Neriah, Michael Karin
Dec 17, 2008·The Journal of Biological Chemistry·Barbara S PaughTomasz Kordula
Feb 26, 2010·International Immunology·Elena VoronovRon N Apte
Jul 19, 2011·Obstetrics and Gynecology International·Kamisha T Woolery, Patricia A Kruk
Sep 12, 2012·Journal of Translational Medicine·Nina MikirovaPaul Taylor
Jun 6, 2014·PloS One·Thomas KalinskiNorbert Nass
Jul 12, 2011·Medicina oral, patología oral y cirugía bucal·Vlaho BrailoMelita Balija
Nov 29, 2007·Future Oncology·Noah M HahnChristopher J Sweeney
Nov 15, 2014·Der Pathologe·T Kalinski
Jul 30, 2014·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Marcela Esquivel-VelázquezJorge Morales-Montor
Feb 11, 2014·Leukemia & Lymphoma·Marco CalvarusoAda Maria Florena
Jan 21, 2015·Seminars in Cancer Biology·Zongwei WangLasse D Jensen
Dec 30, 2008·FEBS Letters·Stéphane PerrierMarie-Paule Vasson
Sep 11, 2014·Journal of Cellular Physiology·Chia-Huei LeeKo-Jiunn Liu
Feb 24, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hong-Yue RenDong-Yan Shen
Jan 29, 2013·Veterinary Immunology and Immunopathology·Paloma Jimena de AndrésLaura Peña
Dec 22, 2015·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Elena Voronov, Ron N Apte
Dec 24, 2015·Neoplasia : an International Journal for Oncology Research·Zach S TempletonBonnie L King
Jan 5, 2011·Trends in Molecular Medicine·Helena KiefelPeter Altevogt
Jul 29, 2008·Mutation Research·Kent HartShanbeh Zienolddiny
Jul 12, 2014·Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents·Suniti MisraSubhash Padhye
Mar 28, 2008·Immunological Reviews·Ron N Apte, Elena Voronov
Oct 9, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Bo SuHongyang Wang
Apr 26, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hui KongWeiping Xie
Sep 14, 2007·Biochemical Pharmacology·Christine L TamChristine A Towle
Sep 18, 2008·The Journal of General Virology·Valentina Dell'osteMarisa Gariglio
Sep 12, 2015·British Journal of Cancer·Mao Watanabe TokumotoKosei Hirakawa
Jul 8, 2010·European Journal of Cell Biology·Laurence FeldmeyerHans-Dietmar Beer
Jul 5, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yanan LiJiucun Wang
Aug 21, 2013·Critical Reviews in Oncology/hematology·Wim CeelenMarc Mareel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis